Onconetix, Inc. (ONCO) company profile
Close on Nov 17, 2026Market cap $11.85MP/E –Yield –
About Onconetix
Pharmaceutical Preparations, SIC 2834
Onconetix, Inc. is a commercial-stage biotechnology enterprise specializing in the research, development, and commercialization of solutions for men’s health and oncology. The company focuses primarily on Proclarix, an in vitro protein-based diagnostic blood test for prostate cancer that assesses risk to help determine the necessity of patient biopsies following inconclusive prostate-specific antigen results. While previously developing treatments such as a daily combination therapy for benign prostatic hyperplasia, the organization has discontinued those initiatives to concentrate on its core oncology diagnostic asset. Target end users include physicians, patients, and local diagnostic laboratories.
The firm conducts sales in Europe, where its diagnostic product is CE-marked and authorized under the In Vitro Diagnostic Regulation, and it anticipates marketing the test within the United States through an established laboratory licensing agreement. Corporate headquarters are situated in Cincinnati, Ohio, while manufacturing activities are outsourced to third-party commercial suppliers.
Summary of the business section of Onconetix's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Onconetix, Inc.
- Founded
- 2018
- Headquarters
- Cincinnati, OH
- Address
- 201 E. Fifth Street, Suite 1900 45202
- Phone
- (513) 620-4101
- Website
- onconetix.com
- Employees
- 12, Dec 31, 2022
- Industry
- Pharmaceutical Preparations
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- MaloneBailey, LLP, Houston, Texas
Stock & identifiers
- Ticker
- ONCO
- Former tickers
- BWV until Jan 12, 2024
- Exchange
- Nasdaq
- IPO date
- Feb 23, 2022
- Shares outstanding
- 4M, Aug 13, 2026
- Public float
- $3.60M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-10 reverse, May 21, 2026; 1-for-5 reverse, Mar 25, 2026; 1-for-85 reverse, Jun 13, 2025; 1-for-40 reverse, Sep 24, 2024
- SEC CIK
- 1782107
- CUSIP
- 68237Q203
- ISIN
- US68237Q2030
- FIGI
- BBG00PNSYQJ2
- Share class FIGI
- BBG00PNSYQK0
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| David Allan White | Chief Executive Officer | – |
| Christian Bruhlmann | Chief Strategy Officer | 611,372 |
| Ralph Schiess | Interim CEO, CSO | 673,365 |
| Sammy Dorf | Director | – |
| Sarah Romano | Director | – |
| Andrew John Oakley | Director | 638 |
| Simon Tarsh | Director | 40 |
| Timothy R. Ramdeen | Director | 40 |
| Thomas Meier | Director | 39 |
Executive compensation, fiscal 2025
Summary compensation table from the latest proxy statement
| Executive | Salary | Bonus | Total | vs. prior year |
|---|---|---|---|---|
| Ralph Schiess Former Chief Executive Officer and Former Chief Science Officer | $163.94K | – | $163.94K | -46% |
| Karina Fedasz Interim Chief Financial Officer and Former Interim Chief Executive Officer | $307.06K | $45.00K | $352.06K | +79% |
Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Feb 23, 2022
- Offer price
- $9.00
- Securities offered
- 2,222,222
- Gross proceeds
- $20.00M
- Exchange
- Nasdaq
- First trading day
- Feb 22, 2022
- Lock-up ends (est.)
- Aug 21, 2022
“The initial public offering price is $9.00 per share.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
See a number that looks wrong?